The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Johnson & Johnson Announces USPTO Action Related to REMICADE®

23-Feb-2015 | Source : Johnson & Johnson | Visits : 6734
NEW BRUNSWICK, NJ – Johnson & Johnson announced in a press release receipt of a further action from the US Patent and Trademark Office (USPTO) regarding the re-examination of US Patent No. 6,284,471 (‘471) relating to REMICADE® issuing a final rejection of the patent.

We have sixty days to respond to this action and will do so. Currently the ‘471 patent expires in September 2018. We believe the ‘471 patent is valid and, if necessary, will pursue all available appeals.

Related Articles